Is Shilpa Medicare a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Shilpa Medicare Ltd is a good quality company .

Is Shilpa Medicare undervalued or overvalued?

The key valuation ratios of Shilpa Medicare Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone .

What is Shilpa Medicare share price return in the past 10 years?

Shilpa Medicare Ltd share price has appreciated 13.1% annually (CAGR) over the past ten years.

Is Shilpa Medicare a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Shilpa Medicare Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

Shilpa Medicare Ltd - Stock Valuation and Financial Performance

Name: Shilpa Medicare
Brand: Shilpa Medicare

BSE: 530549 | NSE: SHILPAMED | Pharmaceuticals & Drugs | Small Cap

Place order

Shilpa Medicare Share Price

₹935.80 55.90 6.35%
as on 21-Nov'24 16:59

10 Year X-Ray of Shilpa Medicare:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	17.9%	19.7%	15.3%	11.1%	10.5%	12.4%	10.7%	5.9%	0.8%	5.5%	-
Value Creation Index ⓘ	0.3	0.4	0.1	-0.2	-0.3	-0.1	-0.2	-0.6	-0.9	-0.6	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	614	716	779	789	733	908	901	1,146	1,050	1,152	1,214
Sales YoY Gr.	-	16.7%	8.8%	1.2%	-7%	23.8%	-0.8%	27.1%	-8.3%	9.7%	-
Adj EPS ⓘ	9.4	14.4	13	12	10.7	17.7	10.9	5.9	-4.9	2.5	6.3
YoY Gr.	-	53.8%	-10.1%	-7.6%	-10.6%	65.6%	-38.4%	-46.3%	-182.6%	NA	-
BVPS (₹) ⓘ	70.9	82.9	123.2	133.1	146.9	163.1	181.4	209.9	205.4	208.4	238.1
Adj Net Profit ⓘ	72.2	111	104	97.7	87.3	145	89	51	-42.1	21.3	61
Cash Flow from Ops. ⓘ	68.8	129	37.5	44.9	147	124	46.9	105	180	135	-
Debt/CF from Ops. ⓘ	2.7	0.7	6.4	4.3	1.3	3.1	18	6.5	4.4	6.9	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	7.2%	9.4%	8.5%	9.7%
Adj EPS ⓘ	-13.9%	-25.6%	-39.2%	NA
BVPSⓘ	12.7%	7.2%	4.7%	1.4%
Share Price	13.1%	25.5%	18.6%	149.9%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	15.3	18.7	12.8	9.4	7.7	11.4	6.3	3.1	-2.3	1.2	2.8
Op. Profit Mgn % ⓘ	20.6	22.5	20.8	19.2	21.1	23.6	19.1	17.4	8.4	20.5	24.3
Net Profit Mgn % ⓘ	11.6	15	12.9	12.1	11.5	15.8	9.7	4.4	-3.9	1.9	5
Debt to Equity ⓘ	0.3	0.1	0.2	0.2	0.2	0.3	0.6	0.4	0.5	0.5	0.1
Working Cap Days ⓘ	158	158	193	237	266	230	286	280	309	273	124
Cash Conv. Cycle ⓘ	56	59	84	116	141	126	170	165	186	159	38

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 2.80%

Sales growth is good in last 4 quarters at 10.52%

Sales growth has been subdued in last 3 years 8.52%

Net Profit has been subdued in last 3 years -39.24%

Latest Financials - Shilpa Medicare Ltd.

	Standalone	Consolidated
TTM EPS (₹)	7.3	6.3
TTM Sales (₹ Cr.)	377	1,214
BVPS (₹.) ⓘ	275.2	238.1
Reserves (₹ Cr.) ⓘ	2,682	2,318
P/BV ⓘ	3.20	3.70
PE ⓘ	120.73	140.87

From the Market
52 Week Low / High (₹)	313.55 / 959.95
All Time Low / High (₹)	0.39 / 959.95
Market Cap (₹ Cr.)	8,605
Equity (₹ Cr.)	9.8
Face Value (₹)	1
Industry PE ⓘ	43

Management X-Ray of Shilpa Medicare:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.81

1.38

12.90

90.41

7.90

* Pledged shares as % of Promoter's holding (%)

Valuation of Shilpa Medicare

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Shilpa Medicare

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	614	716	779	789	733	908	901	1,146	1,050	1,152
Operating Expenses ⓘ	487	556	618	638	579	693	729	948	962	916
Manufacturing Costs	56	67	79	89	95	118	129	172	167	135
Material Costs	323	366	372	356	257	278	271	383	416	407
Employee Cost	82	90	128	149	176	197	235	264	286	281
Other Costs ⓘ	26	33	39	44	51	101	94	128	92	92
Operating Profit ⓘ	126	160	162	151	154	215	172	197	88	236
Operating Profit Margin (%)	20.6%	22.3%	20.7%	19.2%	21.0%	23.6%	19.1%	17.2%	8.4%	20.5%
Other Income ⓘ	7	11	29	33	16	22	40	21	31	17
Interest ⓘ	4	4	3	3	4	5	22	41	59	92
Depreciation ⓘ	21	23	31	37	42	44	54	80	95	108
Exceptional Items ⓘ	0	-2	-5	0	20	0	61	9	0	6
Profit Before Tax ⓘ	108	140	146	137	136	188	195	102	-38	54
Tax ⓘ	35	36	42	34	26	33	49	42	-7	22
Profit After Tax	73	105	104	103	110	155	146	61	-31	32
PAT Margin (%)	11.8%	14.6%	13.4%	13.0%	14.9%	17.0%	16.2%	5.3%	-2.9%	2.8%
Adjusted EPS (₹)	9.6	14.1	13.4	12.9	13.8	19.2	18.1	7.0	-3.7	3.7
Dividend Payout Ratio (%)	6%	4%	4%	5%	7%	6%	6%	16%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	547	639	987	1,085	1,198	1,329	1,479	1,822	1,783	1,809
Share Capital ⓘ	8	8	8	8	8	8	8	9	9	9
Reserves ⓘ	539	632	979	1,077	1,189	1,321	1,471	1,814	1,775	1,800
Minority Interest	14	2	-3	-5	-8	-8	-11	-11	-9	-9
Debt	161	74	235	166	168	330	718	557	633	921
Long Term Debt	102	0	143	68	81	165	474	354	289	560
Short Term Debt	58	74	92	98	87	165	243	203	344	361
Trade Payables	76	106	112	104	81	93	77	146	143	175
Others Liabilities ⓘ	107	109	141	149	172	245	371	362	354	187
Total Liabilities ⓘ	905	931	1,472	1,499	1,610	1,989	2,632	2,875	2,904	3,083
Fixed Assets
Gross Block	476	582	705	793	853	986	1,421	1,727	1,847	1,947
Accumulated Depreciation	160	189	213	259	295	336	311	385	478	562
Net Fixed Assetsⓘ	316	393	492	534	558	650	1,111	1,342	1,368	1,385
CWIP ⓘ	222	92	141	210	429	666	541	506	655	719
Investmentsⓘ	66	94	253	140	2	10	21	34	43	40
Inventories	131	134	190	189	188	226	333	355	320	345
Trade Receivables	81	125	171	220	204	247	234	386	324	392
Cash Equivalents	18	11	100	74	95	45	124	34	22	30
Others Assetsⓘ	71	81	126	132	135	144	269	218	172	172
Total Assets ⓘ	905	931	1,472	1,499	1,610	1,989	2,632	2,875	2,904	3,083

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	69	129	37	45	147	124	47	105	180	135
PBT ⓘ	108	140	146	137	136	188	195	102	-38	54
Adjustment ⓘ	26	21	17	19	28	42	6	109	148	206
Changes in Working Capital ⓘ	-40	-3	-93	-70	19	-63	-106	-72	103	-84
Tax Paid ⓘ	-25	-30	-34	-41	-36	-42	-48	-34	-32	-41
Cash Flow From Investing Activity ⓘ	-195	-109	-262	-9	-196	-290	-404	-285	-233	-167
Capex	-145	-114	-116	-137	-78	-345	-349	-331	-225	-172
Net Investments	-56	4	-149	125	98	50	-56	14	-9	4
Others ⓘ	6	1	3	4	-216	5	1	31	2	1
Cash Flow From Financing Activityⓘ	136	-20	313	-61	10	176	436	83	46	47
Net Proceeds from Shares ⓘ	86	0	172	0	0	0	0	297	0	0
Net Proceeds from Borrowing ⓘ	30	0	128	-56	-68	82	381	-121	-27	123
Interest Paid ⓘ	-4	-4	-3	-3	-4	-4	-22	-41	-58	-92
Dividend Paid ⓘ	-5	-11	-5	-7	0	-17	0	-9	-10	0
Others ⓘ	28	-5	21	5	82	115	78	-42	141	16
Net Cash Flow ⓘ	10	0	88	-25	-39	10	79	-98	-7	16

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	15.4	17.66	12.85	9.93	9.59	12.23	10.41	3.67	-1.71	1.78
ROCE (%)	17.9	19.69	15.28	11.13	10.45	12.38	10.73	5.94	0.8	5.49
Asset Turnover Ratio	0.78	0.79	0.65	0.53	0.47	0.5	0.39	0.42	0.36	0.38
PAT to CFO Conversion(x)	0.95	1.23	0.36	0.44	1.34	0.8	0.32	1.72	N/A	4.22
Working Capital Days
Receivable Days	44	52	69	90	106	91	97	99	124	114
Inventory Days	75	67	75	87	94	83	113	110	117	105
Payable Days	95	91	107	111	131	114	114	106	127	142

Shilpa Medicare Ltd Stock News

Shilpa Medicare Ltd FAQs

What is the share price of Shilpa Medicare?

Company share prices are keep on changing according to the market conditions. The closing price of Shilpa Medicare on 21-Nov-2024 16:59 is ₹935.8.

What is the market cap of Shilpa Medicare?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Nov-2024 16:59 the market cap of Shilpa Medicare stood at ₹8,604.6.

What is the P/E ratio of Shilpa Medicare?

The latest P/E ratio of Shilpa Medicare as of 21-Nov-2024 16:59 is 120.7.

What is the P/B ratio of Shilpa Medicare?

The latest P/B ratio of Shilpa Medicare as of 21-Nov-2024 16:59 is 3.20.

What is the 52-week high and low of Shilpa Medicare?

The 52-week high of Shilpa Medicare is ₹960.0 and the 52-week low is ₹313.6.

What is the TTM revenue of Shilpa Medicare?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Shilpa Medicare is ₹377.2 ( Cr.) .

About Shilpa Medicare Ltd

Shilpa Medicare, established in 1987, has carved a niche for itself in the exceedingly competitive and quality-conscious sphere of pharmaceuticals manufacturing. It produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

The company has earned its spurs as a successful and reliable partner within the pharmaceutical industry. Buyers within the country and from across the borders count on its fast track integrated process development and finely honed expertise of its skilled and experienced personnel. The company is already exporting to USA, Canada, Australia, Japan and European countries viz., Germany, Switzerland, Netherlands, Belgium, Spain, Greece, Cyprus, Italy, United Kingdom etc., South American countries like Mexico, Brazil, Columbia etc, African countries like Kenya, Nigeria and West Indies etc, Asian countries like Singapore, Taiwan, China, Malaysia, Thailand and closer to home to Iran, Egypt, Pakistan and Bangladesh. Shilpa Medicare is synergizing strength through tie-ups for manufacturing products and co-marketing rights, for it believes in working together and sharing success.

Being proactive in approach, the company continually seeks out enquiryâ€™s for development of new products drawing from the extensive knowledge-base of its qualified and experienced people as well as sophisticated facilities.

Product range of the company includes:

Oncology AP's

Anastrozole
Bicalutamide
Carboplatin
Gemcitabine HCI
Irinotecan HCl Trihydrate
Oxaliplatin
Temozolomide
Cisplatin
5-Fluoro
Bortezomib
Capecitabine
Decarbazine
Docetaxel
Gefitinib
Hydroxy urea
Imatinib Mesylate
Lenalidomide
Letrozole
Methotrexate
Thalidomide
Topotecan HCl
Zoledronic acid

General APIs

Ambroxol HCl
Ticlopidine HCl
Buflomedil HCl
Nifedipine
Lamivudine
Sildenafil Citrate
Terfenadine
Acebrophylline
Phenylephrine HCl
Ursodeoxycholic acid

PRODUCTS UNDER DEVELOPMENT (Oncology)

Bendamustine Cladribine
Decitabine Disodium Pamidronate
Epirubicin Exemustane
Fludarabine Phosphate Idarubicine
Paclitaxel Pemetrexed
Lomustine Methotrexate
Pamidronic acid Tandutinib

NUTRITIONAL SUPPLEMENTS

Chromium picolinate Chromium polynicotinate

DRUG INTERMEDIATES

Trans-4-amino cyclohexanol
2-Amino-3,5-dibromobenzaldehyde
1,3,5-Trimethoxy Benzene
1,3,5-Tribromo Benzene
7-ethyl camptothecin
7-ethyl-10-hydroxy camptothecin

Awards & Achievements:

Karnataka State Govt. 'Best Enterpreneur Award'.
Govt. of India 'Best Enterpreneur Award'.
â€˜Star Export Houseâ€™ Status from Ministry of Commerce and Industry, Govt. of India
'cGMP' Certificates from W.H.O. for 20 API's
'Best Export Award' from Visvesvaraya Industrial Trade Centre, Bangalore, Govt. of Karnataka, INDIA
'Outstanding Industrial Award' from Indian Junior Chamber.
'Registration with 'Russian Health Authority' for Ambroxol HCl
'Certificate of Suitability' received from EDQM for Ambroxol HCl (R0-CEP 2004-201-Rev 00)
'Certificate of Suitability' received from EDQM for Ticlopidine HCl (R0-CEP 2005-004-Rev 00)
'Certificate of Suitability' received from EDQM for Carboplatin (R0-CEP 2006-212-Rev 00)
Patent application on Irinotecan HCl Trihydrate 'An improved process for the preparation of Irinotecan HCl Trihydrate' published as WO2006016203 on date 2006-02-16
Patent file for Gemcitabine HCl and Anastrozole manufacturing process.
Filed ASMF/EDMF of Gemcitabine HCl over 21 EU countries
Filed ASMF/EDMF of Irinotecan HCl Trihydrate HCl over 27 EU countries
Filed ASMF/EDMF of Oxaliplatin HCl over 11 EU countries
'Best District Export Award' received from FKCCI, Bangalore on 16.06.2007
Korean FDA Approved for Gemcitabine HCl & Ambroxol HCl
COS received from EDQM for Buflomedil HCl (R0-CEP 2006-080-Rev.00)
COS received from EDQM for Oxaliplatin EP (R0-CEP 2006-201-Rev.00)
'Best District Export Award' received from FKCCI, Bangalore on 20.06.2008.
COS received from EDQM for Gemcitabine HCl EP (R0-CEP 2006-222-Rev 00)
2010 - Shilpa Medicare Limited was granted certificate of GMP Compliance of Manufacturer for Gemcitabine Hydrochloride
2012 - Shilpa Medicare Ltd has been conferred First Prize of the National Energy Conservation Award-2012 in the Drugs & Pharmaceuticals Sector from Ministry of Power, New Delhi.